{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:34:53Z","timestamp":1784309693988,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Centre for Cancer Biomarkers, University of Bergen, research council of Norway","award":["223250"],"award-info":[{"award-number":["223250"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s41669-022-00369-9","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T02:02:31Z","timestamp":1663639351000},"page":"77-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["\u201cDon\u2019t Think Twice, It\u2019s All Right\u201d: Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1587-9674","authenticated-orcid":false,"given":"Jiyeon","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-0440","authenticated-orcid":false,"given":"John","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"369_CR1","unstructured":"National Institute for Health and Care Excellence (NICE). Appraising life-extending, end of life treatments. 2009 [cited 2021 Dec 2]. Available from: https:\/\/www.nice.org.uk\/guidance\/gid-tag387\/documents\/appraising-life-extending-end-of-life-treatments-paper2."},{"key":"369_CR2","unstructured":"House of Commons Committee of Public Accounts. Cancer Drugs Fund twentieth report of session 2015-16 HC 583. [cited 2021 Dec 2]. Available from: https:\/\/publications.parliament.uk\/pa\/cm201516\/cmselect\/cmpubacc\/583\/58302.htm."},{"key":"369_CR3","unstructured":"Claxton K. Pharmaceutical pricing: early access, The Cancer Drugs Fund and the role of NICE. Cent Health Econ Univ York [Internet]. 2016 [cited 2021 Dec 2]. Available from: http:\/\/www.york.ac.uk\/media\/che\/documents\/policybriefing\/Drug_prices.pdf."},{"key":"369_CR4","doi-asserted-by":"crossref","unstructured":"Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund. Ann Oncol Off J Eur Soc Med Oncol [Internet]. 2017 Aug 1 [cited 2022 Apr 19];28(8):1738\u201350. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28453615\/.","DOI":"10.1093\/annonc\/mdx110"},{"key":"369_CR5","unstructured":"National Institute for Health and Care Excellence (NICE). Cancer Drugs Fund [Internet]. [cited 2022 Apr 25]. Available from: https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance\/cancer-drugs-fund."},{"key":"369_CR6","doi-asserted-by":"publisher","first-page":"S493","DOI":"10.1016\/j.jval.2019.09.491","volume":"22","author":"N Doolub","year":"2019","unstructured":"Doolub N, Gupta S, Lohmann S, Khogeer B, Grosvenor A. PCN296 out with the old and in with the new: the evolution of the Cancer Drugs Fund. Value Health. 2019;22:S493.","journal-title":"Value Health"},{"key":"369_CR7","unstructured":"NHS England. Appraisal and funding of cancer drugs from July 2016 [Internet]. [cited 2021 Dec 2]. Available from: https:\/\/www.england.nhs.uk\/publication\/cdf-sop-16\/."},{"key":"369_CR8","unstructured":"National Institute for Health and Care Excellence (NICE). Specification for CDF data collection arrangements [Internet]. [cited 2021 Dec 2]. Available from: https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisal-guidance\/cancer-drugs-fund\/data-collection-specification.pdf."},{"key":"369_CR9","unstructured":"NICE. PMG9 addendum\u2014final amendments to the NICE technology appraisal methods guide to support the new Cancer Drugs Fund arrangements [Internet]. 2018 [cited 2022 Jan 10]. Available from: https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/process-and-methods-guide-addendum.pdf."},{"key":"369_CR10","unstructured":"Consultation on proposals for a new Cancer Drugs Fund (CDF) operating model from 1st April 2016. [cited 2021 Dec 6]. Available from: https:\/\/www.engage.england.nhs.uk\/consultation\/cdf-consultation\/supporting_documents\/cdfconsultationdoc.pdf."},{"key":"369_CR11","unstructured":"SACT Homepage [Internet]. [cited 2021 Nov 30]. Available from: http:\/\/www.chemodataset.nhs.uk\/home."},{"key":"369_CR12","unstructured":"Public Health England. The National Cancer Registration and Analysis Service: a guide to cancer data and working with us. 2020 [cited 2021 Dec 21]. Available from: www.facebook.com\/PublicHealthEngland."},{"key":"369_CR13","doi-asserted-by":"crossref","unstructured":"Kang J, Cairns J. Protocol for data extraction: how real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy. BMJ Open [Internet]. 2022 Jan 1 [cited 2022 Jan 6];12(1):e055985. Available from: https:\/\/bmjopen.bmj.com\/content\/12\/1\/e055985.","DOI":"10.1136\/bmjopen-2021-055985"},{"key":"369_CR14","doi-asserted-by":"crossref","unstructured":"Morrell L, Wordsworth S, Schuh A, Middleton MR, Rees S, Barker RW. Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals. BMC Health Serv Res [Internet]. 2018 May 31 [cited 2021 Dec 2];18(1):1\u20139. Available from: https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-018-3162-2.","DOI":"10.1186\/s12913-018-3162-2"},{"key":"369_CR15","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the processes of technology appraisal [Internet]. 2018 [cited 2022 May 15]. Available from: https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/technology-appraisal-processes-guide-apr-2018.pdf."},{"key":"369_CR16","doi-asserted-by":"publisher","unstructured":"Phillippo DM, Dias S, Ades AE, Welton NJ. Assessing the performance of population adjustment methods for anchored indirect comparisons: a simulation study. Stat Med [Internet]. 2020 [cited 2021 Nov 29]. Available from: https:\/\/doi.org\/10.1002\/sim.8759.","DOI":"10.1002\/sim.8759"},{"key":"369_CR17","doi-asserted-by":"crossref","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Mak [Internet]. 2018 Feb 1 [cited 2021 Nov 29];38(2):200. Available from: \/pmc\/articles\/PMC5774635\/.","DOI":"10.1177\/0272989X17725740"},{"key":"369_CR18","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen J, Kefalas P. Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate. J Mark Access Health Policy [Internet]. 2019 Jan 1 [cited 2021 Nov 29];7(1):1635842. Available from: \/pmc\/articles\/PMC6609347\/.","DOI":"10.1080\/20016689.2019.1635842"},{"key":"369_CR19","doi-asserted-by":"crossref","unstructured":"Latimer NR. PCN317\u2014the Cancer Drugs Fund: key uncertainties, data collection plans, analytical methods and use of the systematic anti-cancer therapy (SACT) real world data set. Value Health [Internet]. 2018 Oct 1 [cited 2021 Nov 26];21:S68. Available from: http:\/\/www.valueinhealthjournal.com\/article\/S1098301518336994\/fulltext.","DOI":"10.1016\/j.jval.2018.09.399"},{"key":"369_CR20","unstructured":"Macdonald H, Goldacre B. Does the reformed Cancer Drug Fund generate evidence on effectiveness? A cross-sectional analysis on publicly accessible documentation. medRxiv [Internet]. 2020 Mar 8 [cited 2021 Dec 6];2020.03.06.19014944. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.06.19014944v1."},{"key":"369_CR21","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual [Internet]. 2022 [cited 2022 Feb 22]. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/."},{"key":"369_CR22","doi-asserted-by":"crossref","unstructured":"Montilla S, Xoxi E, Russo P, Cicchetti A, Pani L. Monitoring registries at Italian Medicines Agency: fostering access, guaranteeing sustainability. Int J Technol Assess Health Care [Internet]. 2015 Dec 8 [cited 2022 Aug 16];31(4):210\u20133. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26646859\/.","DOI":"10.1017\/S0266462315000446"},{"key":"369_CR23","unstructured":"Sultana J, Trifiro G, et al. What can real-world evidence contribute to regulatory science in pre- and post-marketing setting? Pharmadvances. 2020 [cited 2022 August 13]; 2(2):51\u201358. http:\/\/www.pharmadvances.com\/wp-content\/uploads\/2020\/07\/Sultana.pdf"},{"key":"369_CR24","doi-asserted-by":"crossref","unstructured":"Makady A, van Acker S, Nijmeijer H, de Boer A, Hillege H, Klungel O, et al. Conditional financing of drugs in the Netherlands: past, present, and future\u2014results from Stakeholder Interviews. Value Health [Internet]. 2019 Apr 1 [cited 2022 Aug 13];22(4):399\u2013407. Available from: http:\/\/www.valueinhealthjournal.com\/article\/S1098301519300749\/fulltext.","DOI":"10.1016\/j.jval.2018.11.016"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00369-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-022-00369-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00369-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:58:16Z","timestamp":1676393896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-022-00369-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["369"],"URL":"https:\/\/doi.org\/10.1007\/s41669-022-00369-9","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"23 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jiyeon Kang is supported by the Centre for Cancer Biomarkers, University of Bergen, funded by the Research Council of Norway grant number (223250). The funder is not involved in any aspect of the study conduct or the decision to submit the paper for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the London School of Hygiene and Tropical Medicine on 14 November 2019 (17315).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study used publicly available data. Consent to participate is not applicable in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data analysed during the current study are available on the National Institute for Health and Care Excellence website [].","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Both authors contributed to conceptualising and designing the study. JK analysed the data and drafted the manuscript. JC revised the manuscript for important intellectual content and contributed to the methodology.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}